Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Vedanta Biosciences or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.